Article Per Year (5 Year)
p-Index From 2021 - 2026
0.61
P-Index
This Author published in this journals
All Journal Indonesian Journal of Cardiology Heart Science Journal
Prameswari, Hawani Sasmaya
Unknown Affiliation
Health Professions Immunology & microbiology Medicine & Pharmacology

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

 1 
2023 Indonesian Guidelines for Heart Failure Treatment: Working Group on Heart Failure and Cardiometabolic Diseases, Indonesian Heart Association Hasanah, Dian Yaniarti; Zulkarnain, Edrian; Arifianto, Habibie; Prameswari, Hawani Sasmaya; Suciadi, Leonardo Paskah; Yamin, Paskariatne Probo Dewi; Pratikto, Rarsari Soerarso; Nauli, Siti Elkana; Putri, Vebiona Kartini Prima; Soedarsono, Wahyu Aditya; Sarastri, Yuke
Jurnal Kardiologi Indonesia Vol 45 No 2 (2024): April - June, 2024
Publisher : The Indonesian Heart Association

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.30701/ijc.1671

Abstract

Heart failure is a health problem with high mortality and morbidity rates in developed and developing countries such as Indonesia. The prevalence of heart failure itself is increasing because patients who experience acute heart failure can progress to chronic heart failure. Guidelines-Directed Medical Therapy (GDMT) with recommended doses is still underutilized in heart failure patients with reduced ejection fraction (HFrEF). In Indonesia itself, even though it has a fairly high rate of use of ACE-inhibitors (ACE-I) or angiotensin receptor blockers (ARB), Indonesia has the lowest rate of use of β-blockers and aldosterone inhibitors (also called Mineralocorticoid Receptor Antagonists, MRA) of the entire ASIAN-HF registry.84 Therefore, the writing of this guideline was carried out as an effort to provide practical guidance regarding the diagnosis, assessment and management of acute and chronic heart failure. Thus, it is hoped that efforts can be made to prevent the increase in prevalence and reduce the number of rehospitalization with complete management. This book was written as an update to the 2020 Guideline for the Management of Heart Failure: Indonesian Heart Association. The sources of our updates came from many references and literatures carried out by each contributor and reviewed by EBM team.
Effects of early ivabradine therapy in patients with acute heart failure: A meta-analysis and systematic review Nuraini, Yulianna Cahya; Irnizarifka, Irnizarifka; Prameswari, Hawani Sasmaya; Simangunsong, Robby Martin
Heart Science Journal Vol. 6 No. 1 (2025): Challenges in Managing Acute Heart Failure
Publisher : Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.hsj.2025.006.01.10

Abstract

BACKGROUND: Although ivabradine is the agent of choice for reducing heart rate, its use in acute heart failure patients remains unclear. OBJECTIVES: To evaluate the potential of in-hospital ivabradine administration in reducing heart rate, the risk of rehospitalization, mortality, and clinical profile in acute heart failure patients using a meta-analysis approach. METHODS: The study was designed as a meta-analysis conducted from August to September 2024. We selected several database sources for the search strategy, including PubMed, Google Scholar, ProQuest, British Medical Journal, and American Journal of Cardiology. Data on the outcomes of ivabradine treatment compared to standard therapy were collected to determine cumulative point estimates. For statistical analysis, we used the Mantel–Haenszel test for categorical data or inverse variance for continuous data. RESULTS: We included 11 articles in the study. Our findings indicated that, in comparison to the standard therapy group, the ivabradine group was associated with improvements in resting heart rate, a reduction in the risk of rehospitalization, a decrease in cardiovascular mortality, a reduction in all-cause mortality, a shorter length of stay, improvements in New York Heart Association (NYHA) classification, better Left Ventricular Ejection Fraction (LVEF), and improved B-type Natriuretic Peptide (BNP) / N-terminal pro b-type Natriuretic Peptide (NT-proBNP) levels. CONCLUSION: In conclusion, this study has revealed the beneficial effects of using ivabradine for the treatment of acute heart failure.  TRANSLATE with x English Arabic Hebrew Polish Bulgarian Hindi Portuguese Catalan Hmong Daw Romanian Chinese Simplified Hungarian Russian Chinese Traditional Indonesian Slovak Czech Italian Slovenian Danish Japanese Spanish Dutch Klingon Swedish English Korean Thai Estonian Latvian Turkish Finnish Lithuanian Ukrainian French Malay Urdu German Maltese Vietnamese Greek Norwegian Welsh Haitian Creole Persian     TRANSLATE with COPY THE URL BELOW Back EMBED THE SNIPPET BELOW IN YOUR SITE Enable collaborative features and customize widget: Bing Webmaster Portal Back
Effects of early ivabradine therapy in patients with acute heart failure: A meta-analysis and systematic review Nuraini, Yulianna Cahya; Irnizarifka, Irnizarifka; Prameswari, Hawani Sasmaya; Simangunsong, Robby Martin
Heart Science Journal Vol. 6 No. 1 (2025): Challenges in Managing Acute Heart Failure
Publisher : Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.hsj.2025.006.01.10

Abstract

BACKGROUND: Although ivabradine is the agent of choice for reducing heart rate, its use in acute heart failure patients remains unclear. OBJECTIVES: To evaluate the potential of in-hospital ivabradine administration in reducing heart rate, the risk of rehospitalization, mortality, and clinical profile in acute heart failure patients using a meta-analysis approach. METHODS: The study was designed as a meta-analysis conducted from August to September 2024. We selected several database sources for the search strategy, including PubMed, Google Scholar, ProQuest, British Medical Journal, and American Journal of Cardiology. Data on the outcomes of ivabradine treatment compared to standard therapy were collected to determine cumulative point estimates. For statistical analysis, we used the Mantel–Haenszel test for categorical data or inverse variance for continuous data. RESULTS: We included 11 articles in the study. Our findings indicated that, in comparison to the standard therapy group, the ivabradine group was associated with improvements in resting heart rate, a reduction in the risk of rehospitalization, a decrease in cardiovascular mortality, a reduction in all-cause mortality, a shorter length of stay, improvements in New York Heart Association (NYHA) classification, better Left Ventricular Ejection Fraction (LVEF), and improved B-type Natriuretic Peptide (BNP) / N-terminal pro b-type Natriuretic Peptide (NT-proBNP) levels. CONCLUSION: In conclusion, this study has revealed the beneficial effects of using ivabradine for the treatment of acute heart failure.  TRANSLATE with x English Arabic Hebrew Polish Bulgarian Hindi Portuguese Catalan Hmong Daw Romanian Chinese Simplified Hungarian Russian Chinese Traditional Indonesian Slovak Czech Italian Slovenian Danish Japanese Spanish Dutch Klingon Swedish English Korean Thai Estonian Latvian Turkish Finnish Lithuanian Ukrainian French Malay Urdu German Maltese Vietnamese Greek Norwegian Welsh Haitian Creole Persian     TRANSLATE with COPY THE URL BELOW Back EMBED THE SNIPPET BELOW IN YOUR SITE Enable collaborative features and customize widget: Bing Webmaster Portal Back
Co-Authors Arifianto, Habibie Hasanah, Dian Yaniarti Irnizarifka Leonardo Paskah Suciadi Nuraini, Yulianna Cahya Pratikto, Rarsari Soerarso Putri, Vebiona Kartini Prima Sarastri, Yuke Simangunsong, Robby Martin Siti Elkana Nauli Soedarsono, Wahyu Aditya Yamin, Paskariatne Probo Dewi Zulkarnain, Edrian